AJOVY is available in an autoinjector. Learn more

You had searched for:

There were no results matching the query.

You can also browse the topics below to find what you are looking for.

Patient Profiles


Maura

Anna

Need help answering a question?

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

Post hoc analyses of the long-term open-label extension study of migraine days for selected dosing periods1

For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Select the data:

Quarterly dosing: Mean number of weekly migraine days in weeks 1-2 vs weeks 11-121*

CHRONIC MIGRAINE

Chart describing the Chronic migraine post hoc analysis from the long-term open-label extension study of mean number of weekly migraine days from weeks 1-2 vs weeks 11-12 with quarterly dosing.

4.0 mean baseline weekly migraine days

Weeks 1-2

Weeks 11-12

 

EPISODIC MIGRAINE

Chart describing the Episodic migraine post hoc analysis from the long-term open-label extension study of mean number of weekly migraine days from weeks 1-2 vs weeks 11-12 with quarterly dosing.

2.3 mean baseline weekly migraine days

Weeks 1-2

Weeks 11-12

Monthly dosing: Mean number of weekly migraine days during weeks 1-3 vs week 4 at months 3, 6, 9, and 151*

CHRONIC MIGRAINE

Chart describing the Chronic migraine post hoc analysis from the longterm open-label extension study of mean number of weekly migraine days from weeks 1-3 vs week 4 at month 3, 6, 9, and 15 with monthly dosing. Chart describing the Chronic migraine post hoc analysis from the longterm open-label extension study of mean number of weekly migraine days from weeks 1-3 vs week 4 at month 3, 6, 9, and 15 with monthly dosing.

4.0 mean baseline weekly migraine days

Weeks 1-2

Weeks 11-12

EPISODIC MIGRAINE

 Chart describing the Episodic migraine post hoc analysis from the longterm open-label extension study of mean number of weekly migraine days from weeks 1-3 vs week 4 at month 3, 6, 9, and 15 with monthly dosing.  Chart describing the Episodic migraine post hoc analysis from the longterm open-label extension study of mean number of weekly migraine days from weeks 1-3 vs week 4 at month 3, 6, 9, and 15 with monthly dosing.

2.3 mean baseline weekly migraine days

Weeks 1-2

Weeks 11-12

*Study design: Of the patients who rolled over from the HALO studies, 611 from the HALO CM study (quarterly, n=306; monthly, n=305) and 432 from the HALO EM study (quarterly, n=217; monthly, n=215) had received AJOVY during the respective HALO study and were included in the post hoc analysis during the long-term open-label extension study.1

Suggestions to explore next

AJOVY was also studied in patients with an inadequate response to 2 or more classes of prior preventive treatments2

See clinical trial results

Only 4 injection days per year with quarterly dosing

Dosing for AJOVY